论文部分内容阅读
目的探讨XP方案,卡培他滨(xeloda)、顺铂(CDDP)和FP方案,5-氟尿嘧啶(5-FU)、顺铂(CDDP),治疗晚期胃癌的疗效及安全性。方法选择115例符合条件的晚期胃癌患者,随机分为两组:治疗I组采用XP方案,口服卡培他滨(xeloda)1.0g,每日2次,d1～14;顺铂(CDDP)20mg/(m2·d),静脉滴注,d1～5,共1个疗程;治疗Ⅱ组采用FP方案:5-氟尿嘧啶(5-Fu)750mg/m2持续静脉滴注d1～5、顺铂(CDDP)20mg/(m2·d),静脉滴注,d1～5,共1个疗程。随访近期(21d,63d),远期(疗程结束后360d),观察两组患者的平均有效率(RR),总生存期(OS),无症状生存期(PFS)及主要不良反应的发生情况。结果治疗Ⅰ组(XP组)和治疗Ⅱ组(FP组)的有效率(RR)两组比较差异无统计学意义(P>0.05),总生存期(OS)、无症状生存期(PFS)两组对比无显著差异,而不良反应的发生率经比较治疗I组(XP组)明显低于治疗Ⅱ组(FP组),两组比较差异有统计学意义(P<0.05)。结论治疗I组(XP组)对于晚期胃癌患者不良反应较轻、并且临床使用方便,患者依从性好值得推广。
Objective To investigate the efficacy and safety of XP regimen, xeloda, CDDP and FP regimen, 5-fluorouracil (5-FU) and cisplatin (CDDP) in the treatment of advanced gastric cancer. Methods One hundred and fifteen patients with advanced gastric cancer who were eligible were randomly divided into two groups: treatment group I received XP regimen, oral xeloda 1.0g, twice daily, d1-14, and CDDP 20mg (m2 · d), intravenous drip, d1 ~ 5, a total of 1 course of treatment; the treatment group Ⅱ FP program: 5-Fu 750mg / m2 continuous intravenous infusion of d1 ~ 5, ) 20mg / (m2 · d), intravenous drip, d1 ~ 5, a total of 1 course of treatment. The patients were followed up for a long time (21d, 63d) and long term (360d after the end of treatment). The average effective rate (RR), overall survival (OS), asymptomatic survival (PFS) and the incidence of major adverse reactions . Results There was no significant difference in RR between the two groups (P> 0.05), the overall survival (OS), asymptomatic survival (PFS) There was no significant difference between the two groups, but the incidence of adverse reactions was significantly lower in group I (XP group) than that in group II (FP group). There was significant difference between the two groups (P <0.05). Conclusions Treatment group I (XP group) has less adverse reactions to patients with advanced gastric cancer and is easy to use in clinical practice. It is worthy of promotion in patients with compliance.